Remopharma
Turnover is estimated at about €3.0m, probably between €2.2m and €4.1m. The abbreviated format does not state turnover.
Balance sheet
balance sheet total €3.7m on 31-12-2025in €m
in euro
Position in the sector
60.2%
Higher than 74% of the 13,303 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
1.83
Higher than 59% of the 13,162 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
6.6%
Higher than 60% of the 13,223 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter · Staff: middle half
Staff
€65,124
Staff costs divided by the average number of full-time equivalents.
level
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 200916 months |
|---|---|---|---|---|---|
| 622,368 | 621,226 | 616,547 | 131,539 | ||
| 447,138 | 474,889 | 464,668 | 100,741 | ||
| 503,456 | 160,898 | 157,581 | 567,488 | ||
| 39,114 | -58,564 | - | - | ||
| 690,255 | 833,990 | 637,198 | 90,744 | ||
| 60.2% | 59.3% | 51.3% | 18.0% | ||
| 1.83 | 2.32 | 1.85 | 1.48 | ||
| 1.22 | 1.53 | 1.23 | 1.05 | ||
| 0.66 | 0.69 | 0.95 | 4.56 | ||
| 10.9% | 15.1% | 18.2% | 15.9% | ||
| 6.6% | 8.9% | 9.4% | 2.9% | ||
| 5.53 | 10.06 | 10.08 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 200916 months |
|---|---|---|---|---|---|
| Balance sheet: assets | |||||
20/58 |
3.7m | 3.3m | 3.3m | 767,116 | |
21/28 |
2.1m | 1.8m | 1.9m | 488,715 | |
21 |
122,779 | 148,179 | 173,579 | 208,000 | |
22/27 |
2.0m | 1.7m | 1.7m | 280,715 | |
22 |
1.2m | 1.1m | 1.2m | 196,296 | |
23 |
843,549 | 553,225 | 488,769 | 477 | |
24 |
16,562 | 18,252 | 11,380 | 83,942 | |
29/58 |
1.5m | 1.5m | 1.4m | 278,401 | |
3 |
507,696 | 497,991 | 464,978 | 82,009 | |
30/36 |
507,696 | 497,991 | 464,978 | 82,009 | |
40/41 |
333,208 | 255,574 | 277,146 | 42,275 | |
40 |
300,944 | 220,225 | 235,708 | 39,468 | |
41 |
32,264 | 35,350 | 41,438 | 2,806 | |
50/53 |
426,222 | 501,222 | 376,222 | - | |
54/58 |
233,124 | 194,009 | 252,574 | 152,593 | |
490/1 |
17,718 | 14,745 | 13,487 | 1,525 | |
| Balance sheet: equity and liabilities | |||||
10/49 |
3.7m | 3.3m | 3.3m | 767,116 | |
10/15 |
2.2m | 2.0m | 1.7m | 137,968 | |
10/11 |
1,000 | 1,000 | 1,000 | 116,000 | |
100 |
- | - | - | 116,000 | |
13 |
2.2m | 2.0m | 1.7m | 21,968 | |
130/1 |
- | - | 0 | - | |
130 |
- | - | - | 11,600 | |
1311 |
- | - | 0 | - | |
132 |
118 | 118 | 118 | - | |
133 |
2.2m | 2.0m | 1.7m | 10,368 | |
17/49 |
1.5m | 1.3m | 1.6m | 629,148 | |
17 |
629,311 | 716,145 | 831,724 | 440,646 | |
170/4 |
629,311 | 716,145 | 831,724 | 440,646 | |
42/48 |
827,712 | 629,551 | 747,208 | 187,657 | |
42 |
124,793 | 132,755 | 149,913 | 36,080 | |
44 |
628,904 | 447,431 | 499,077 | 77,346 | |
440/4 |
628,904 | 447,431 | 499,077 | 77,346 | |
45 |
73,891 | 49,280 | 98,063 | 6,040 | |
450/3 |
18,138 | 11,003 | 61,105 | 6,040 | |
454/9 |
55,753 | 38,277 | 36,958 | - | |
47/48 |
125 | 85 | 155 | 68,191 | |
492/3 |
1,250 | 1,832 | 3,452 | 845 | |
| Income statement | |||||
9900 |
1.1m | 965,347 | 932,226 | 161,901 | |
62 |
455,871 | 329,855 | 303,705 | - | |
630 |
205,996 | 179,294 | 160,548 | 78,773 | |
640/8 |
24,011 | 14,266 | 11,974 | 30,363 | |
9901 |
416,371 | 441,932 | 455,999 | 52,766 | |
75/76B |
11,596 | 14,555 | 6,441 | 31 | |
75 |
11,596 | 14,555 | 6,441 | 31 | |
65/66B |
112,541 | 61,768 | 61,166 | 24,783 | |
65 |
112,541 | 61,768 | 61,166 | 24,783 | |
9903 |
315,427 | 394,719 | 401,274 | 28,013 | |
67/77 |
74,285 | 99,124 | 97,154 | 6,045 | |
9904 |
241,142 | 295,595 | 304,120 | 21,968 | |
9905 |
241,142 | 295,595 | 304,120 | 21,968 | |
| Appropriation of the result | |||||
9906 |
241,142 | 295,595 | 304,120 | 21,968 | |
691/2 |
241,142 | 295,595 | 304,120 | 21,968 | |
6920 |
- | - | - | 11,600 | |
6921 |
241,142 | 295,595 | 304,120 | 10,368 | |
| Social balance sheet | |||||
9087 |
7 | 6.1 | 5.3 | - | |
Hours worked1013 |
12,209 | 9,528 | 9,221 | - | |
| Document | |||||
The full notes are in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 18-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankThe accounts were filed on 18-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00403475.
Subsidies and aid
Flemish government 2024 to 2025, 2 entries, €3,340 awarded, €3,340 paid
| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 1 | €2,531 | €2,531 |
| 2024 | 1 | €809 | €809 |
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 |
|---|---|---|---|
| Employees at the balance-sheet date | 9 | 9 | 7 |
| full-time | 4 | 4 | 3 |
| part-time | 5 | 5 | 4 |
| in full-time equivalents | 7 | 6.8 | 5.8 |
| 7 | 6.1 | 5.3 | |
| On a permanent contract | 8 | 8 | 6 |
| Joined | 2 | 6 | 4 |
| Left | 2 | 4 | 4 |
Source: social balance sheet in the 2023 to 2025 annual accounts
Securities and guarantees
on own assets and for others| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debts guaranteed by Belgian public bodies | €754,104 | - | - |
Source: notes to the 2023 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Tangible fixed assets | €503,456 | €160,898 | €157,581 |
| Financial fixed assets | €0 | - | - |
| €205,996 | €179,294 | €160,548 |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on Remopharma
The operating result for 2025 is 6% lower than in 2024 and the lowest since 2023. It is the second fall in a row.
Debt's share of the balance-sheet total falls from 40.7% to 39.8%. Equity and debt are higher.